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This study aims to examine the current practice of General practitioners (GPs)/primary care physicians in
opportunistic screening for prostate cancer (PC) by digital rectal examination(DRE) and Prostate Specific Antigen
(PSA) testing and identify any difference in screening practice.
Printed copies and/or electronic versions of a survey was distributed amongst 438 GPs throughout Australia in
2012. Statistical analyses (Wilcoxon rank-sum test, Fisher’s exact test or Pearson chi-square test)were performed by
outcomes and GP characteristics.There were a total of 149 responses received (34%), with similar gender distribution
in rural and metropolitan settings. 74% GPs believed PSA testing was at least ‘somewhat effective’ in reducing PC
mortality with annual PSA screening being conducted by more GPs in the metropolitan setting compared to the
rural GPs (35% vs 18.4%), while 25% of rural GPs would not advocate routine PSA screening. When examining the
concordance between DRE and PSA testing by gender of GP, the male GPs reported performing PSA testing more
frequently than DRE in patients between ages 40 to 69 (p = 0.011).
Urology Society guidelines (77.2%) and College of GPs (73.2%) recommendations for PC screening were thought to
be at least ‘somewhat useful’. Although reference ranges for PSA tests were felt to be useful, the majority (65.8%)
found it easier to refer to an urologist due to the disagreements in guidelines.
In conclusion, the current guidelines for PSA screening appear to cause more confusion due to their conflicting
advice, leaving GPs to formulate their own practice methods, calling for an urgent need for uniform collaborative
guidelines.Introduction
Australia and New Zealand have the highest incidence
of prostate cancer (PC) worldwide with cancer specific
five year survival rates exceeding 90% (Ferlay et al. 2010;
2012). This high prevalence of PC in Australia is consid-
ered to be driven by high rates of opportunistic PSA
screening as evidenced by the recent large increases in
PSA testing in Australia, with a substantial proportion of
detected cancers being lower grade tumours in younger
men (Ranasinghe et al. 2014). At the other end of the
age spectrum the recent Concord Health and Ageing in
Men Project (CHAMP) study in Australia reported that
a significant proportion of men over 70 years were
screened for PC (Litchfield et al. 2012).* Correspondence: weranja@gmail.com
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reproduction in any medium, provided the origScreening for PC using prostate specific antigen (PSA)
is highly controversial. Due to the conflicting results
from the European Randomized Study of Screening
for Prostate Cancer (ERSPC) and the Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial
the recent guidelines such as the U.S. Preventive Services
Task Force (USPSTF) recommended against the use of
PSA screening in all age groups, owing to limited evidence
in reducing PC specific mortality and harms attributable
to over diagnosis and overtreatment (Schroder et al. 2012;
Andriole et al. 2012; Chou et al. 2011). Similarly, in
Australia, there are conflicting guidelines from the
Urology Society of Australia and New Zealand (USANZ)
who advocate the use of DRE and PSA in men between
the ages of 50–69 and the General Practice guidelines
who do not recommend the routine use of either DRE or
PSA in any age group (USANZ 2009; RACGP).is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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conducted by General Practitioners (GPs) in the Primary
Care Setting. The lack of clear guidelines may signifi-
cantly impact clinical practice and negatively influence
outcomes for patient’s physicians and healthcare sys-
tems. Therefore our aim was to examine the current
practice of GPs and Primary Care Physicians in the use
of routine DRE and PSA screening as part of opportun-
istic screening for PC. Furthermore, we aimed to identify
any difference in screening practice between GPs by
their practice setting (metropolitan and rural) and gen-
der. In addition, we investigated the usefulness of the
perceived utility of PSA adjuncts such as age PSA ranges,
median PSA, prostate health index (PHI) (Stephan et al.
2014) in the Primary Care Setting.
Methods
Study population
After ethics approval, a survey reviewing PSA screening
was distributed amongst 438 GPs throughout Australia.
Printed copies of the questionnaire and a web link to an
online questionnaire were distributed using local GP Prac-
tice Based Research Networks via the National Institute
of Integrative Medicine, Victoria (n = 130), Centre for
Primary Health Care and Equity, NSW (n = 52) and the
University of Newcastle, NSW(n = 136) in 2012. When
mailed out, a reply paid envelope was included and
three reminders were mailed out post initial survey. In
addition, 120 questionnaires were distributed at the
UroGP conference (University of Melbourne, Austin
Hospital, Melbourne Australia), a local GP’s meeting in
Melbourne. No incentives were provided for any of the
respondents.
Questionnaire
This was developed in the USA to assess the perceptions
and attitudes of PSA screening and treatment in an aver-
age risk man (a man with no significant co-morbidities,
no family history (FHx) of PC and >10 yrs life expectancy)
and piloted amongst a small number of GPs (n = 10) in
Australia (Additional file 1). Ethics approval was sought
from the Ethics and Research Committee at the Alfred
Hospital.
The question items on the survey included the charac-
teristics of the respondents such as age group, location
of practice (metropolitan, regional or rural), gender and
race. The effectiveness of PC screening modalities PSA
and DRE as well as radical prostatectomy, radiotherapy
and active surveillance in reducing cancer mortality due
to prostate cancer in an average risk man was assessed.
The respondents were also asked about the recommen-
dation of utilisation of PSA screening and DRE as the
“best practice” in an average risk man for the age groups
of 40–69 yrs, 50 to 59 yrs, 70–75 yrs and >75 years andthe appropriate frequency of screening. In addition, the in-
fluence of the recommendations regarding PC screening
from the leading organisations and the perceived utility of
the effectiveness of reference ranges of median PSA, age-
related PSA range, free to total PSA and the utilisation of
prostate health index were also assessed.
Statistical analysis
Comparisons by gender and location (metropolitan versus
rural based GPs) were made with the Wilcoxon rank-sum
test for ordinal response outcomes and the Fisher’s exact
test or Pearson chi-square test for binary response out-
comes. Testing the equality of intervals of PSA and DRE
testing was performed with the Wilcoxon matched-pairs
signed-ranks test. Percentages quoted in the text include
participants who did not answer the specified question,
unless otherwise noted. All tests were two-sided with a
significance level set at <0.05. Analysis was performed
with Stata v.12.0 SE (Statacorp, College Station, TX).
Ethical standards
Ethics approval was sought from the Ethics and Research
Committee at the Alfred Hospital.
Results
Characteristics of respondents
There were a total of 149 responses received (34%), the
majority (65.1%) were UroGP conference attendees
(Table 1). Of the total respondents 68.5% were males,
worked in a metropolitan setting (62.4%) and were from
the state of Victoria (49%). 38.9% of the respondents
were between the ages of 50 to 59 and the mean number
of years in practice was 26.2 (median 27.5 years; range
1–55 years). The distribution of gender was almost identi-
cal in metropolitan and rural areas (female GPs in metro-
politan regions 29.7%, in rural areas 29.6%). Detailed
characteristics are demonstrated in Table 1.
Beliefs in current therapy
Seventy four percent of GPs believed that PSA testing
was at least ‘somewhat effective’ in reducing PC mortal-
ity in an average risk male with similar results for digital
rectal examinations (DRE). In terms of treatment, 70%
of GPs thought that radical prostatectomy and active
surveillance were at least somewhat effective in reducing
PC mortality in an average risk man. External beam
radiotherapy was thought to be effective by 59% of re-
spondents, though there were a relatively high number
of “not sure” respondents for this modality (Figure 1).
For active surveillance, there was a difference in
perceived effectiveness by gender (female GPs) and by
practice setting (Metropolitan) compared to their peers
(Table 2).
Table 1 Characteristics of respondents





Not answered 4 (2.7%)
Area of practice*
Metropolitan 93 (62.4%)
Combined rural 55 (36.9%)
Regional 34 (22.8%)
Rural 21 (14.1%)
Not answered 1 (0.7%)
Age
≤40 21 (14.1%)
41 to 49 23 (15.4%)
50 to 59 58 (38.9%)
60 to 69 34 (22.8%)
≥70 11 (7.4%)
Not answered 2 (1.3%)
Years in practice
<10 years 18 (12.1%)
10 – 20 years 30 (20.1%)
>20 years 96 (64.4%)
Not answered 5 (3.4%)
State
Victoria 73 (49.0%)
New South Wales 37 (24.8%)
Queensland 13 (8.7%)
Western Australia 9 (6.0%)
South Australia 9 (6.0%)




Other/Not answered 12 (8.1%)
Breakdown of responses by recruitment
UroGP conference 97/120 (80.8%)
National Institute of Integrative
Medicine, Victoria
17/130 (13.1%)
Centre for Primary Health Care
and Equity, NSW
14/52 (26.9%)
University of Newcastle, NSW 21/136 (15.4%)
*Due to small sample size, GPs working in the regional and rural sectors were
combined and labelled as rural practice in the analysis.
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There were no significant differences in DRE based
screening by GP gender or practice setting for menbetween 40 to 69 years of age (Table 3). However, there
were significant differences in frequency of PSA screen-
ing by practice setting but not by GP gender (Table 4).
Furthermore, when examining the concordance between
DRE and PSA testing by GP gender, male GPs reported
performing PSA testing more frequently than DRE in
patients aged 40 to 69 (p = 0.011) while female GPs prac-
tised similar interval times between tests (p = 0.608)
(Table 4a/b). These results were similar for patients be-
tween ages 50 to 59; male GPs (p = 0.002), female GPs
(p = 0.739). The concordance between frequencies of
DRE and PSA screening are seen in the Additional file 2:
Table S1(a) and (b).
Influential organisations
The majority of the GPs surveyed thought that USANZ
(77.2%) and the College of GPs (73.2%) recommen-
dations were at least ‘somewhat influential’. There were
no significant differences in gender or practice setting
when comparing which guidelines were the most useful.
Interestingly, just over half (51.0%) of GPs disagreed
with the USPSTF recommendations against PSA and DRE
for screening in asymptomatic men.
Types of PSA testing
Of the PSA tests available, the majority of GPs believed
that age-related PSA ranges (73.2%) and free-to-total
PSA ratio (78.5%) were effective, whilst almost half
(40.3%) of the surveyed GPs thought that the median
PSA level provided was not. Only 16.1% of GPs had
heard of the PHI and of these only 20.8% used it in clinical
practice.
Furthermore, 61.1% of GPs thought that 5-alpha-
reductase-inhibitors would affect the PSA test, whilst 32.2%
were unsure of the effect or did not provide a response.
Only 6.7% of GPs believed the drugs had no effect on a
patient’s PSA level.
Referral to an urologist
Nearly two thirds (65.8%) of GPs found it easier to refer
to an urologist if there was any confusion regarding re-
sults due to the current screening guidelines. There was
a significant difference in willingness to refer by GP gen-
der with female GPs more likely to refer (87.5% vs. 65.6%,
p = 0.011; Table 5). There was also a difference observed
in metropolitan vs. non-metropolitan (76.7% vs. 63.3%,
p = 0.094) though this did not reach significance.
Discussion
Screening for PC remains highly controversial due to the
lack of consensus from clinical practice guidelines. Thus,
some guidelines advocate regular screening for PC,
whilst other established bodies such as the USPSTF do
not recommend screening in any age group (Schroder
Figure 1 Beliefs in current therapy for the management of PC in Australia.
Ranasinghe et al. SpringerPlus  (2015) 4:78 Page 4 of 7et al. 2012; Andriole et al. 2012; Chou et al. 2011), lead-
ing to decrease in PC screening in the USA (Aslani et al.
2013). In Australia, the leading bodies have completely
opposing guidelines. The USANZ policy in 2009 recom-
mended starting a single PSA test and DRE at 40 years
whilst the college of GP’s do not recommend PSA
screening or DRE unless the patient specifically requests
it and is clearly counselled (USANZ 2009; RACGP).Thus
a clear message from a peak body is still lacking. Our re-
sults show that as similar proportions of GPs take into
account guidelines from all the major bodies, causing
confusion not only on the frequency of PSA screening
but also whether to conduct DRE and their appropriate
frequency. These conflicts in existing guidelines directly
translate in to significant variations in clinical practice,
leaving GPs to formulate their own practice methods
without any clear guidelines.
In this situation where there are conflicting guidelines,
the decision to screen is strongly biased by Primary
Health Care providers views, rather than those of the pa-
tients, as the latter usually have inadequate knowledge
to make an informed decision (Hoffman et al. 2009; Han
et al. 2013). Our study demonstrates higher rates of PSA
screening in asymptomatic men compared to another
Danish study (Jessen et al. 2013). Certainly GPs views
may be influenced by medical training. Marcella et al.
demonstrated that during medical training, students
generally are very optimistic about the benefits ofTable 2 Perceived effectiveness of active surveillance by gend
Very effective Somewhat effective
Gender
Female GP (%) 17 (44.7) 20 (52.6)
Male GP (%) 24 (28.6) 42 (50.0)
Setting
Metro GP (%) 32 (40.0) 37 (46.3)
Rural GP 9 (20.9) 25 (58.1)
Percentages and p-values calculated only for subjects that gave a response.screening for PC but with increased knowledge, a more
conservative view of screening is adopted (Marcella et al.
2007). While further refinement/consistency of teaching
to medical students regarding other issues such as family
history in PC may help case selection, our findings
clearly highlight the need for more structured collabora-
tive guidelines to help inform GPs well as their patients.
The process of screening should be by promoting in-
formed decision making taking in to account the patient’s
concerns, as some men fear impotence and incontinence
after treatment if diagnosed with cancer (Parchment 2004).
Cultural sensitivity must also be taken into account (Chan
et al. 2003). Interestingly, one study demonstrated, that
when men were provided with sufficient information,
they were less likely to accept a recommendation by a
GP to undergo PSA screening (Gattellari & Ward 2005).
However, the physician’s positive engagement in shared
decision-making, tailored social influences promoting
PC prevention among certain cultures, as well as institu-
tional screening policy, has the potential to increase early
detection and reduce morbidity (Woods et al. 2006).
An intriguing finding in this study was that younger
GPs tend to conduct more regular PSA testing rather
than DRE. An abnormal DRE is sensitive in detecting
PC but when combined with a an abnormal serum PSA
sensitivity is further increased (95%, PPV = 62%) (Martinez
De Hurtado et al. 1995). However, there are a number of
possibilities as to why DRE is not utilised as readily as aer of GP and by setting of practice





Table 3 Frequency of DRE and PSA based screening by location of practice and gender for patients aged 40 to 69
Every year Every 2 years Every 5 years Would not recommend P value Other/not answered
DRE
Setting
0.194Metro GP (%) 25 (34.3) 25 (34.3) 8 (11.0) 15 (20.5) 20
Rural GP 6 (22.2) 8 (29.6) 7 (25.9) 6 (22.2) 28
Gender
0.388
Female GP (%) 10 (32.3) 12 (38.7) 5 (16.1) 4 (12.9) 12
Male GP (%) 21 (31.3) 19 (28.4) 10 (14.9) 17 (25.4) 35
PSA
Setting
0.006Metro GP (%) 35 (49.3) 15 (21.1) 7 (9.9) 14 (19.7) 22
Rural GP (%) 7 (18.4) 14 (36.8) 4 (10.5) 13 (34.2) 17
Gender
0.434Female GP (%) 10 (30.3) 9 (27.3) 7 (21.2) 7 (21.2) 10
Male GP (%) 31 (41.9) 19 (25.7) 4 (5.4) 20 (27.0) 28
Percentages and p-values calculated only for subjects that gave a response.
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subjectivity especially when not performed regularly, due
to difficulty palpating the whole prostate (Koulikov et al.
2012) and limited urology skills as a medical student
(Kaplan et al. 2012). In addition patient factors such as
cultural attitudes to DRE (Consedine et al. 2006) and em-
barrassment of the patient (Parchment 2004) may also
play a role.
PSA is a non-specific test and can be elevated in a num-
ber of benign and inflammatory conditions. ThereforeTable 4 Frequency of PSA screening by gender and location o
aged 50 to 59 (b)
Every year Every 2 years Every 5 years
4(a)
In patients aged 40 to 69:
Setting
Metro GP (%) 35 (49.3) 15 (21.1) 7 (9.9)
Rural GP (%) 7 (18.4) 14 (36.8) 4 (10.5)
Gender
Female GP (%) 10 (30.3) 9 (27.3) 7 (21.2)
Male GP (%) 31 (41.9) 19 (25.7) 4 (5.4)
4(b)
In patients aged 50 to 59:
Setting
Metro GP (%) 48 (64.0) 17 (22.7) 3 (4.0)
Rural GP (%) 16 (36.4) 15 (34.1) 2 (4.6)
Gender
Female GP (%) 18 (52.9) 8 (23.5) 4 (11.8)
Male GP (%) 44 (53.0) 24 (28.9) 1 (1.2)
Percentages and p-values calculated only for subjects that gave a response.many other methods such as age PSA ranges, median
PSA, PHI have been developed and advocated to enhance
the accuracy of detecting PCs (Stephan et al. 2014). How-
ever, no single test is currently accepted as the best modal-
ity and should be interpreted with using judicious clinical
acumen and individualised to the patient. Furthermore,
the USANZ policy recommends taking into account fam-
ily history, ethnicity, DRE and PSA derivatives such as
PSA velocity and free-total PSA ratio when screening for
PC (USANZ 2009).Thus some of these ranges, if not all,f practice for patients aged 40 to 69 (a) and patients
Would not recommend P value Other/not answered
14 (19.7) 0.006 22
13 (34.2) 17
7 (21.2) 0.434 10
20 (27.0) 28
7 (9.3) 0.002 18
11 (25.0) 11
4 (11.8) 0.942 9
14 (16.9) 19
Table 5 Referral to an urologist by gender and location
of practice
Refer Not refer P value Not answered
Setting
Metro GP 66 (76.7) 20 (23.3)
0.094#
7
Rural GP 31 (63.3) 18 (36.7) 6
Gender
Female GP (%) 35 (87.5) 5 (12.5)
0.011*
3
Male GP (%) 61 (65.6) 32 (34.4) 9
*Fisher’s exact test; #Pearson chi-square.
Percentages and p-values calculated only for subjects that gave a response.
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ology laboratories and these results are provided to the re-
ferring GP. Our results suggest that the introduction of
these tests and inclusion of these ranges are likely to cause
more confusion rather than being a helpful guide to GPs
and could possibly lead to more referrals to the urologists
which could even prompt earlier biopsies.
There was a significant discrepancy in PC screening
practice between practice settings, with lower rates of
screening evident in rural areas. This is in keeping with
lower PSA screening and radical prostatectomy rates
leading to poorer survival and mortality outcomes in PC
for males living in rural Australia when compared to
their urban counterparts (Baade et al. 2011). These find-
ings are largely influenced by limited access to resources
for routine screening and the lack of locally available ur-
ology services, a predicament also faced in other coun-
tries (Baldwin et al. 2013; Patel et al. 2010). The role of
the poorly accessible urological service cannot be under-
estimated as this may deter rural GPs from screening
asymptomatic men as readily and adopt their practice
taking into account these limitations in resources. In
addition, the conflict with current screening guidelines
and the possibility that metropolitan males may request
PSA screening more readily than their rural counter-
parts, which may further influence the decision to screen
urban men more readily.
Limitations
The effect that gender and practice location seen in our
study are unlikely to have influenced each other, due to
similar distributions of respondents in each group. One
drawback in our study is the low response rate despite
efforts to increase the response rate such as reminders
(both postal and email) and reply paid postage enve-
lopes. The non-respondents characteristics were not
readily available as the questionnaire was completely an-
onymous. A further limitation of this study is that the
majority of the responses came from a selected group of
GPs who attended the UROGP conference and were
aware of issues in PC, which may have introduced someselection bias in to the study. In addition there was a
skew towards an older GP population answering the
survey.
We did not test the GPs attitudes towards the risks
downstream of PSA testing. In Australia as a high pro-
portion of men with low risk prostate cancer undergo
active surveillance (Evans et al. 2013), the discussions
regarding treatment and diagnosis have to be separated
due to the difficulty of estimating likely mortality bene-
fits without a biopsy and as such downstream effects
such as incontinence and ED need to be discussed once
the decision has been reached that treatment is actually
required.
In conclusion, our study demonstrates that in the
absence of clear guidelines from a peak body, there is
significant variation in current practice in screening for
PC. The conflicting messages given out in these guide-
lines appear to be causing more confusion rather than
providing guidance, leaving GPs to formulate their own
practice methods. These findings call for an urgent need
for uniform guidelines for PC screening practices amongst
GPs which should be formed as collaborative effort by GP
continuing medical education (CME) bodies and all speci-
alities involved in the care of PC. This should be then
followed by a robust education campaign aimed at GPs as
well as individuals. As such, the recent National Health
and Medical Research Council (NHMRC) have attempted
to overcome these variations by publishing recent guide-
lines (NHMRC 2014). However, the practical application
of these guidelines in day to day practice by the GPs is yet
to be determined.Additional files
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